Αποτελέσματα αναζήτησης - "АКТИВНОСТЬ КОМПЛЕМЕНТА"

1

Academic Journal

Profile of antiphospholipid antibodies and complement system in COVID-19 patients of different severity ; Профиль антифосфолипидных антител и состояние системы комплемента у больных COVID-19 разной степени тяжести

Συγγραφείς: N. V. Dolgushina, I. V. Menzhinskaya, O. S. Beznoshchenko, S. M. Mullabayeva, E. A. Gorodnova, L. V. Krechetova, Н. В. Долгушина, И. В. Менжинская, О. С. Безнощенко, С. М. Муллабаева, Е. А. Городнова, Л. В. Кречетова

Πηγή: Medical Immunology (Russia); Том 24, № 2 (2022); 351-366 ; Медицинская иммунология; Том 24, № 2 (2022); 351-366 ; 2313-741X ; 1563-0625

Θεματικοί όροι: компонент C3, компонент C4, COVID-19, complement, component C3, component C4, антифосфолипидные антитела, активность комплемента

Περιγραφή αρχείου: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2465/1530; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2465/9050; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2465/9051; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2465/9052; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2465/9053; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2465/9054; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2465/9055; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2465/9056; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2465/9057; Долгушина Н.В., Кречетова Л.В., Иванец Т.Ю., Вторушина В.В., Инвияева Е.В., Климов В.А., Сухих Г.Т. Влияние иммунного статуса на тяжесть течения COVID-19 // Акушерство и гинекология, 2020. № 9. C. 129-137.; Зайратьянц О.В., Cамсонова М.В., Михалева Л.М., Черняев А.Л., Мишнев О.Д., Крупнов Н.М., Калинин Д.В. Патологическая анатомия COVID-19: Атлас / Под общ. ред. О.В. Зайратьянца. М.: ГБУ «НИИОЗММ ДЗМ», 2020. 140 с.; Abdel-Wahab N., Lopez-Olivo M.A., Pinto-Patarroyo G.P., Suarez-Almazor M.E. Systematic review of case reports of antiphospholipid syndrome following infection. Lupus, 2016, Vol. 25, pp. 1520-1531.; Asakura H., Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int. J. Hematol., 2021, Vol. 113, no. 1, pp. 45-57.; Bohlson S.S., Garred P., Kemper C., Tenner A.J. Complement nomenclature-deconvoluted. Front. Immunol., 2019, Vol. 10, 1308. doi:10.3389/fimmu.2019.01308.; Borghi M.O., Beltagy A., Garrafa E., Curreli D., Cecchini G., Bodio C., Grossi C., Blengino S., Tincani A., Franceschini F., Andreoli L., Lazzaroni M.G., Piantoni S., Masneri S., Crisafulli F., Brugnoni D., Muiesan M.L., Salvetti M., Parati G., Torresani E., Mahler M., Heilbron F., Pregnolato F., Pengo M., Tedesco F., Pozzi N., Meroni P.L. Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front. Immunol., 2020, Vol. 11, 584241. doi:10.3389/fimmu.2020.584241.; Cervera R. Antiphospholipid syndrome. Thromb. Res., 2017, Vol. 151, Suppl. 1, pp. S43-S47.; Choi W.-Y. Mortality rate of patients with COVID-19 based on underlying health conditions. Disaster Med. Public Health Prep., 2021, Vol. 3, pp. 1-16.; Cristiano A., Fortunati V., Cherubini F., Bernardini S., Nuccetelli M. Anti-phospholipids antibodies and immune complexes in COVID-19 patients: a putative role in disease course for anti-annexin-V antibodies. Clin. Rheumatol., 2021, Vol. 40, no. 7, pp. 2939-2945.; Cugno M., Meroni P.L., Gualtierotti R., Griffini S., Grovetti E., Torri A., Panigada M., Aliberti S., Blasi F., Tedesco F., Peyvandi F. Complement activation in patients with COVID-19: A novel therapeutic target. J. Allergy Clin. Immunol., 2020, Vol. 146, no. 1, pp. 215-217.; Devreese K.M.J., Linskens E.A., Benoit D., Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J. Thromb. Haemost., 2020, Vol. 18, no. 9, pp. 2191-2201.; Favaloro E.J., Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-Part I. Semin. Thromb. Hemost., 2020, Vol. 46, no. 7, pp. 757-762.; Galeano-Valle F., Oblitas C.M., Ferreiro-Mazón M.M., Alonso-Muñoz J., del Toro-Cervera J., di Natale M., Demelo-Rodríguez P. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb. Res., 2020, Vol. 192, pp. 113-115.; Gatto M., Perricone C., Tonello M., Bistoni O., Cattelan A.-M., Bursi R., Cafaro G., de Robertis E., Mencacci A., Bozza S., Vianello A., Iaccarino L., Gerli R., Doria A., Bartoloni E. Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. Clin. Exp. Rheumatol., 2020, Vol. 38, no. 4, pp. 754-759.; Gralinski L.E., Bankhead A., Jeng S., Menachery V.D., Proll S., Belisle S.E., Matzke M., Webb-Robertson B.J., Luna M.L., Shukla A.K., Ferris M.T., Bolles M., Chang J., Aicher L., Waters K.M., Smith R.D., Metz T.O., Law G.L., Katze M.G., McWeeney S., Baric R.S. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio, 2013, Vol. 4, no. 4, e00271-13. doi:10.1128/mBio.00271-13.; Gralinski L.E., Sheahan T.P., Morrison T.E., Menachery V.D., Jensen K., Leist S.R., Whitmore A., Heise M.T., Baric R.S. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio, 2018, Vol. 9, no. 5, e01753-18. doi:10.1128/mBio.01753-18.; Harboe M., Mollnes T.E. The alternative complement pathway revisited. J. Cell. Mol. Med., 2008, Vol. 12, no. 4, pp. 1074-1084.; Harzallah I., Debliquis A., Drénou B. Lupus anticoagulant is frequent in patients with COVID-19. J. Thromb. Haemost., 2020, Vol. 18, no. 8, pp. 2064-2065.; Iba T., Warkentin T.E., Thachil J., Levi M., Levy J.H. Proposal of the definition for COVID-19-associated coagulopathy. J. Clin. Med., 2021, Vol. 10, no. 2, 191. doi:10.3390/jcm10020191.; Java A., Apicelli A.J., Liszewski M.K., Coler-Reilly A., Atkinson J.P., Kim A.H., Kulkarni H.S. The complement system in COVID-19: friend and foe? JCI Insight, 2020, Vol. 5, no. 15, e140711. doi:10.1172/jci.insight.140711.; Kouser L., Madhukaran S.P., Shastri A., Saraon A., Ferluga J., Al-Mozaini M., Kishore U. Emerging and novel functions of complement protein C1q. Front. Immunol., 2015, Vol. 6, 317. doi:10.3389/fimmu.2015.00317.; Li G., Fan Y., Lai Y., Han T., Li Z., Zhou P., Pan P., Wang W., Hu D., Liu X., Zhang Q., Wu J. Coronavirus infections and immune responses. J. Med. Virol., 2020, Vol. 92, no. 4, pp. 424-432.; Lo M.W., Kemper C., Woodruff T.M. COVID-19: complement, coagulation, and collateral damage. J. Immunol., 2020, Vol. 205, no. 6, pp. 1488-1495.; Lukawska E., Polcyn-Adamczak M., Niemir Z.I. The role of the alternative pathway of complement activation in glomerular diseases. Clin. Exp. Med., 2018, Vol. 18, no. 3, pp. 297-318.; Magro C., Mulvey J.J., Berlin D., Nuovo G., Salvatore S., Harp J., Baxter-Stoltzfus A., Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl. Res., 2020, Vol. 220, pp. 1-13.; Mastellos D.C., Ricklin D., Lambris J.D. Clinical promise of next-generation complement therapeutics. Nat. Rev. Drug Discov., 2019, Vol. 18, no. 9, pp. 707-729.; Merle N.S., Church S.E., Fremeaux-Bacchi V., Roumenina L.T. Complement system. Part I – Molecular mechanisms of activation and regulation. Front. Immunol., 2015, Vol. 6, 262. doi:10.3389/fimmu.2015.00262.; Mortensen S.A., Sander B., Jensen R.K., Pedersen J.S., Golas M.M., Jensenius J.C., Golas M.M., Jensenius J.C., Hansen A.G., Thiel S., Andersen G.R. Structure and activation of C1, the complex initiating the classical pathway of the complement cascade. Proc. Natl Acad. Sci. USA, 2017, Vol. 114, no. 5, pp. 986-991.; Ohmura K., Oku K., Kitaori T., Amengual O., Hisada R., Kanda M., Shimizu Y., Fujieda Y., Kato M., Bohgaki T., Horita T., Yasuda S., Sugiura-Ogasawara M., Atsumi T. Pathogenic roles of anti-C1q antibodies in recurrent pregnancy loss. Clin. Immunol. 2019, Vol. 203, pp. 37-44.; Potlukova T., Kralikova P. Complement component C1q and anti-C1q antibodies in theory and in clinical practice. Scand. J. Immunol., 2008, Vol. 67, no. 5, pp. 423-430.; Risitano A.M., Mastellos D.C., Huber-Lang M., Yancopoulou D., Garlanda C., Ciceri F., Lambris J.D. Complement as a target in COVID-19? Nat. Rev. Immunol., 2020, Vol. 20, no. 6, pp. 343-344.; Rodríguez-García V., Ioannou Y., Fernández-Nebro A., Isenberg D.A., Giles I.P. Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. Rheumatology, 2015, Vol. 54, no. 11, pp. 2042-2050.; Sun P., Lu X., Xu C., Sun W., Pan B. Understanding of COVID-19 based on current evidence. J. Med. Virol., 2020, Vol. 92, no. 6, pp. 548-551.; Thurman J.M., Holers V.M. The central role of the alternative complement pathway in human disease. J. Immunol., 2006, Vol. 176, no. 3, pp. 1305-1310.; Zhang Y., Xiao M., Zhang S., Xia P., Cao W., Jiang W., Chen H., Ding X., Zhao H., Zhang H., Wang C., Zhao J., Sun X., Tian R., Wu W., Wu D., Ma J., Chen Y., Zhang D., Xie J., Yan X., Zhou X., Liu Z., Wang J., Du B., Qin Y., Gao P., Qin X., Xu Y., Zhang W., Li T., Zhang F., Zhao Y., Li Y., Zhang S. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N. Engl. J. Med., 2020, Vol. 382, no. 17, e38. doi:10.1056/NEJMc2007575.; Zuo Y., Estes S.K., Ali R.A., Gandhi A.A., Yalavarthi S., Shi H., Sule G., Gockman K., Madison J.A., Zuo M., Yadav V., Wang J., Woodard W., Lezak S.P., Lugogo N.L., Smith S.A., Morrissey J.H., Kanthi Y., Knight J.S. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med., 2020, Vol.12, no. 570, eabd3876. doi:10.1126/scitranslmed.abd3876.; https://www.mimmun.ru/mimmun/article/view/2465

Διαθεσιμότητα: https://www.mimmun.ru/mimmun/article/view/2465
https://doi.org/10.15789/1563-0625-POA-2465

View record from BASE

2

Academic Journal

A NEW METHOD TO ASSESS FUNCTIONAL ACTIVITY OF SERUM COMPLEMENT SYSTEM ; НОВЫЙ МЕТОД ОЦЕНКИ ФУНКЦИОНАЛЬНОЙ АКТИВНОСТИ СИСТЕМЫ КОМПЛЕМЕНТА

Συγγραφείς: E. G. Cheremnykh, P. A. Ivanov, M. I. Faktor, N. S. Karpova, E. F. Vasiljeva, K. V. Gusev, O. S. Brusov, Е. Г. Черемных, П. А. Иванов, М. И. Фактор, Н. С. Карпова, Е. Ф. Васильева, К. В. Гусев, О. С. Брусов

Πηγή: Medical Immunology (Russia); Том 17, № 5 (2015); 479-488 ; Медицинская иммунология; Том 17, № 5 (2015); 479-488 ; 2313-741X ; 1563-0625 ; 10.15789/1563-0625-2015-5

Θεματικοί όροι: подсчет клеток, complement activity, Tetrahymena pyriformis, BioLat device, image processing, cell counts, активность комплемента, прибор БиоЛаТ, обработка изображения

Περιγραφή αρχείου: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/936/825; Кулешина О.Н., Андина С.С., Попова О.П., Черемных Е.Г., Козлов Л.В. Активность комплемента при коклюше // Эпидемиология и вакцинопрофилактика, 2013. T. 2, № 69. С. 46-51. [Kuleshina O.N., Andina S.S., Popova O.P., Cheremnykh E.G., Kozlov, L.V. Activity of complement in pertussis]. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccination, 2013, Vol. 2, no. 69, pp. 46-51. (In Russ.)]; Кулешина О.Н., Козлов Л.В., Черемных Е.Г. Универсальный метод определения функциональной активности комплемента человека, лабораторных, домашних и сельскохозяйственных животных, земноводных и птиц // Бюллетень экспериментальной биологии и медицины, 2014. T. 157, № 2. C. 254-257. [Kuleshina O.N., Kozlov L.V., Cheremnykh E.G. Universal method for determining the functional activity of the human complement, laboratory, domestic and farm animals, amphibians and birds]. Byulleten eksperimental`noy biologii i meditsiny = Bulletin of Experimental Biology and Medicine, 2014, Vol. 157, no. 2, pp. 254-257. (In Russ.)]; Оганесян Л.П., Мкртчян Г.М., Сукиасян С.Г., Амбарцумян М.К., Аветисян Г.В., Бояджян А.С. Комплемент как патогенный фактор при посттравматическом стрессе // Биологический журнал Армении, 2009. Т. 1, № 61. С. 48-53. [Oganesyan L.P., Mkrtchyan G.M., Sukiasyan S.G., Ambardzumyan M.K., Avetisyan G.V., Boyajyan A.S. Complement as a pathogenic factor in post-traumatic stress]. Biologicheskiy zhurnal Armenii = Biologist. Journal Armenia, 2009, Vol. 1, no. 61, pp. 48-53. (In Russ.)]; Романов С.В., Козлов Л.В., Дьяков В.Л., Баталова Т.Н., Гузова В.А. Определение активности протеиназ системы комплемента иммуноферментными методами // Биомедицинская химия, 2003. Т. 49, № 6. С. 604-612. [Romanov S.C., Kozlov L.V., Dyakov V.L., Batalova T.N., Guzova B.A. Determination of the activity of proteases of the complement system immunoassay methods]. Biomeditsinskaja himiya = Biomedical Chemistry, 2003, Vol. 49, no. 6, pp. 604-612. (In Russ.)]; Bellander B.M., Singhrao S.K., Ohlsson M., Mattsson P., Svensson M. Complement activation in the human brain after traumatic head injury. J. Neurotrauma. 2001, Vol. 18, no. 12, pp. 1295-1311.; Ducruet A.F., Zacharia B.E., Sosunov S.A., Gigante P.R., Yeh M.L., Gorski J.W., Otten M.L., Hwang R.Y., DeRosa P.A., Hickman Z.L., Sergot P., Connolly E.S.Jr. Complement Inhibition Promotes Endogenous Neurogenesis and Sustained Anti-Inflammatory Neuroprotection following Reperfused Stroke. PLoS ONE, 2012, Vol. 7, no. 6, p. e38664.; Hillmen P. The role of complement inhibition in PNH. American Society of Hematology, 2008, Vol. 1, pp. 116-123.; Ingram G., Loveless S., Howell O.W., Hakobyan S., Dancey B., Harris C.L., Robertson N.P., Neal J.W., Morgan B.P. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathol. Commun., 2014, Vol. 9, no. 2, p. 53.; Loeffler D.A., Camp D.M., Bennett D.A. Plaque complement activation and cognitive loss in Alzheimer’s disease. J. Neuroinflammation 2008, Vol. 11, no. 5, p. 9.; Momeni N., Bergquist J., Brudin L., Behnia F., Sivberg B., Joghataei M.T., Persson B.L. A novel blood-based biomarker for detection of autism spectrum disorders. Transl. Psychiatry., 2012, Vol. 13, no. 2, p. e91.; Palikhe A., Sinisalo J., Seppänen M., Haario H., Meri S., Valtonen V., Nieminen M.S., Lokki M.L. Serum complement c3/c4 ratio, a novel marker for recurrent cardiovascular events. Am. J. Cardiol., 2007, Vol. 1, no. 99 (7), pp. 890-895.; Roos A., Bouwman L.H., van Gijlswijk-Janssen D.J., Faber-Krol M.C., Stahl G.L., Daha M.R., Human IgA activates the complement system via the mannan-binding lectin pathway. J. Immunol.,2001, Vol. 1, no. 167 (5), pp. 2861-2868.; Sinclair I.J.B. The Role of Complement in the Immune Reactions of Paramecium aurelia and Tetrahymena pyriformis. Immunology, 1958, Vol. 1, no. 3, pp. 291-299.; Song C., Dinan T., Leonard B.E. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J. Affect. Disord., 1994, Vol. 30, no. 4, pp. 283-288.; Spivak B., Radwan M., Brandon J., Baruch Y., Stawski M., Tyano S., Weizman A. Reduced total complement haemolytic activity in schizophrenic patients. Psychol. Med., 1993, Vol. 23, no. 2, pp. 315-318.; https://www.mimmun.ru/mimmun/article/view/936

Διαθεσιμότητα: https://www.mimmun.ru/mimmun/article/view/936
https://doi.org/10.15789/1563-0625-2015-5-479-488

View record from BASE

3

Academic Journal